Modality
Fusion Protein
MOA
MDM2i
Target
C5
Pathway
Complement
BCC
Development Pipeline
Preclinical
~Jun 2014
→ ~Sep 2015
Phase 1
~Dec 2015
→ ~Mar 2017
Phase 2
~Jun 2017
→ ~Sep 2018
Phase 3
Dec 2018
→ Jul 2030
Phase 3Current
NCT03194520
2,967 pts·BCC
2023-11→2030-07·Terminated
NCT03646239
503 pts·BCC
2023-03→2027-12·Recruiting
NCT04891198
2,049 pts·BCC
2018-12→TBD·Completed
+1 more trial
6,868 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2027-05-041.1y awayPh3 Readout· BCC
2027-12-151.7y awayPh3 Readout· BCC
2030-07-124.3y awayPh3 Readout· BCC
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Complet…
P3
Not yet…
P3
Recruit…
P3
Termina…
Catalysts
Ph3 Readout
2027-05-04 · 1.1y away
BCC
Ph3 Readout
2027-12-15 · 1.7y away
BCC
Ph3 Readout
2030-07-12 · 4.3y away
BCC
RecruitingCompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03194520 | Phase 3 | BCC | Terminated | 2967 | Safety |
| NCT03646239 | Phase 3 | BCC | Recruiting | 503 | VA |
| NCT04891198 | Phase 3 | BCC | Completed | 2049 | eGFR |
| NCT07511012 | Phase 3 | BCC | Not yet recr... | 1349 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| ARG-1250 | Argenx | Phase 2 | C5 |